Today's focus

1、$BABA-SW (09988.HK) $：Revenue in the first quarter was solid compared with the same period last year.Cloud business revenue growth10%，Taobao and TaobaoM2CMerchandiseGMVGrowth excess40%

BABA-SW reported revenue of 205.555 billion yuan for the three months ended June 30, 2022, which remained stable year-on-year, mainly due to a 1 per cent year-on-year decline in Chinese business segment revenue to 141.935 billion yuan, partly offset by a 10 per cent year-on-year increase in cloud business revenue to 17.685 billion yuan. The operating profit for the period is RMB 24.943 billion, the net profit attributable to common shareholders is RMB 22.739 billion, the net profit is RMB 20.298 billion, and the non-GAAP net profit is RMB 30.252 billion.

2、$China Evergrande Group (03333.HK) $Return the land use right of Guangzhou Evergrande football field

China Evergrande Group announced that on August 3, 2022, the Group signed a termination agreement with the transferee, according to which the original contract was terminated and the land use right of the site was returned by the Group, and the transferee will pay a total of RMB 5.52 billion yuan. It is reported that the site is located in Xie Village District, Panyu District, Guangzhou City, including four sub-plots, with a total area of 499113 square meters and a construction land area of 301062 square meters. Under the original contract, the transferor was granted the land use right of the site for commercial and sports use for a period of 40 years, and the land use right for commercial land for a period of 50 years, calculated from the date of delivery of the site to the transferor (i.e. 24 July 2020). The Group has started construction on the site, including, but not limited to, the construction of Guangzhou Evergrande Football Stadium, which is a professional football field with at least 80,000 seats on the sports land as required by the transferor in the original contract.

3、$Guangzhou Automobile Group (02238.HK) $：7Monthly car sales22.01Ten thousand vehiclesSales of new energy vehiclesYear-on-year increase of 127.26% to27100 vehicles

Guangzhou Automobile Group announced that KuaiBao produced and sold in July 2022. The company's car production in July 2022 was 233621, up 42.69 percent over the same period last year. This year's cumulative output was 1.385276 million, up 18.89 percent over the same period last year. July car sales were 220104, up 21.93 percent over the same period last year. Cumulative sales this year were 1.37003 million, up 13.50 percent from the same period last year. Among them, sales of new energy vehicles in July were 27064, up 127.26% from January to July, and the cumulative sales were 140399, up 121.25% over the same period last year. In July, GAC Aian sold 25033 vehicles, up 138.27% from January to July, with a cumulative sales volume of 125284 vehicles, an increase of 134.74% over the same period last year.

4、$BeiGene, Ltd. (06160.HK) $Product revenue increased by 120% to $304.5 million in the second quarter, R & D expenses reached $378.2 million

BeiGene, Ltd. issued a statement saying that in the three months to June 30, 2022, revenue was $341.6 million, up 127.7 per cent from a year earlier. Revenue for the six months ended June 30, 2022 was $648 million. The company's R & D expenditure in the second quarter was US $378.2 million, an increase of 6.2% over the same period last year.

5、$INNOVENT BIO (01801.HK) $The total product income in the second quarter exceeded 1 billion yuan, reached a multi-project strategic cooperation and licensing agreement with Sanofi Group, and will be invested at a premium of 600 million euros.

INNOVENT BIO announced that in the second quarter of 2022, the company achieved a total product income of more than 1 billion yuan, and has been approved for commercial product portfolio to continue to grow in volume. On August 4, 2022, the Group reached a multi-project strategic cooperation and licensing agreement with Sanofi Group to jointly develop two high-potential antineoplastic drugs, SAR408701 (Tusamitamab Ravtansine). The clinical development and commercialization of anti-CEACAM5 antibody-drug conjugate (ADC) and SAR444245 (non-alpha biased IL-2) in China, including exploring a series of clinical studies combined with the company's PD-1 inhibitor Dabeshu ®(Xindirizumab injection), aimed at accelerating the development and market access of innovative therapies for the benefit of Chinese cancer patients.

6、Greentown China (03900.HK) $The total contract sales in the first seven months is about 140.1 billion yuan

Greentown China announced that in July, Greentown Group achieved sales of 5572 sets of self-investment projects, with a sales area of about 750000 square meters, with a monthly sales amount of 23 billion yuan (the same below), with an average sales price of 30661 yuan per square meter. In the first seven months of this year, Greentown Group obtained a contract sales area of about 4.05 million square meters, with a contract sales value of 105.2 billion yuan. Among them, the amount of rights and interests belonging to Greentown Group is about 56.3 billion yuan. Together with the construction agent project, the total contract sales area is about 6.58 million square meters, with a total contract sales amount of 140.1 billion yuan, a year-on-year decrease of 28%.

7、$CSPC Pharmaceutical (01093.HK) $The clinical study of Mingfule in the treatment of acute ischemic stroke in Ⅲ phase reached the preset main end point.

CSPC Pharmaceutical announced that the phase Ⅲ clinical study of Mingfule (recombinant human TNK tissue plasminogen activator for injection) for the treatment of acute ischemic stroke, independently developed by the non-wholly-owned stone drug Mingfule, reached the preset main end point. Based on the research results, the Group has submitted an application for a pre-listing license meeting to the State Drug Administration. In addition, it is planned to continue to develop Mingfule in indications such as ischemic stroke bridging test, deep venous thrombosis, pulmonary embolism, and central retinal artery occlusion combined with endovascular therapy.

8、$Nuocheng Jianhua-B (09969.HK) $Expected medium-term consolidated income growth of not less than 132.2%

Nuocheng Jianhua-B announced that the group is expected to achieve a comprehensive income of not less than 236 million yuan for the six months ending June 30, 2022, an increase of not less than 132.2% compared with about 101.7 million yuan for the same period in 2021. This is mainly due to the increase in sales of Obutinib. And the consolidated net loss attributable to the shareholders of the company for the six months ended June 30, 2022 shall not exceed approximately RMB 495 million, an increase of no more than 136.4% compared with the consolidated net loss of approximately RMB 209.4 million attributable to the shareholders in the same period in 2021.

Financial data

CK Hutchison (00001) calculated net profit in the first half of the year on a post-IFRS16 basis of about 19.088 billion yuan with an interim interest of HK $0.84.

CK Asset (01113) medium-term net profit increased 55% to HK $12.936 billion interim interest of HK $0.43

Bay area Development (00737) medium-term net profit fell 38% year-on-year to 177 million yuan interim interest 5.75%

Dacheng Foods (03999) realized a profit attributable to shareholders of 33.802 million yuan in the first half of the year.

Faraday (09638) medium-term adjusted EBITDA reached 69 million euros, an increase of 30.1% over the same period last year.

BeiGene, Ltd. (06160) second quarter product revenue increased by 120% to US $304.5 million, R & D expenses reached US $378.2 million.

MGM China (02282) medium-term net loss of HK $2.404 billion increased by 38.70% over the same period last year.

Performance forecast

Nuocheng Jianhua-B (09969) expects medium-term comprehensive income growth of not less than 132.2%

Lihua Holdings Group (01346) expects a net profit of about $4.7 million to $5.3 million in the first half of the year, a net profit of $1.7 million in the same period last year.

Tianbao Energy (01671) profit warning: expected medium-term equity shareholders should share a loss of 9.2 million yuan

Yongsheng Medical (01612) profit Police: it is estimated that the net consolidated loss attributable to the owners of the company in the medium term ranges from HK $40 million to HK $45 million.

Victoria Harbour Environmental Technology (01845) profit Alert: expected medium-term net loss of $25.7 million-$29.7 million

Cofco Jiakang (01610) profit warning: expected medium-term biological assets loss of about 460 million yuan after fair value adjustment

Capital Financial Holdings (08239) earnings warning: medium-term loss is expected to increase by about 194%

Huiji Group (00610) expects net profit to fall sharply in the first half compared with the same period last year.

National United Resources (00254) Yingxi: it is expected that losses will turn into profits in the medium term.

Iron cargo (01029) issued a profit warning and expected profit attributable to shareholders in the first half of the year (excluding asset impairment) of US $30 million to US $40 million.

Operation data

The total contract sales of Greentown China (03900) in the first 7 months is about 140.1 billion yuan.

China Overseas Land & Investment (00688) July contract property sales of 17.468 billion yuan fell 23% year-on-year.

Rongxin China (03301) realized contract sales of 7.57 billion yuan in July.

China overseas Hongyang Group (00081) accumulated contract sales of 23.408 billion yuan from January to July decreased by 50.8% year on year.

Lu Jin (01098): mainland property sales of 14.674 billion yuan fell 44% in the first half of the year compared with the same period last year.

Increase and decrease holdings

Man Wah (01999) gets 2 million shares increased by Chairman Huang Minli.

PICC Property and Casualty (02328) lost 7.424 million shares by SchrodersPLC

Resume trading and suspend trading

Ten parties Holdings (01831) entered into a loan capitalization agreement with creditors and resumed trading on August 5.

Change of equity

Hubei Port, the controlling shareholder of China Trading Group (01719), intends to transfer no more than 22% of the company's shares.

Merger and acquisition and sale

Far East Development (00035) acquired land development rights in Hong Kong Sai Ying Pun for HK $1.24 billion

Additional rights issue

Yongyao Group Holdings (08022) intends to raise HK $500000 by allocating 25 million shares at a premium of about 100.00%.

Xinyi Power Storage (08328) plans to issue shares on a "10 supply 1" basis, with a net maximum of about HK $393 million.

Investment and operation

INNOVENT BIO (01801) reached a multi-project strategic cooperation and licensing agreement with Sanofi

CSPC Pharmaceutical (01093): the clinical study of Mingfule in the treatment of acute ischemic stroke in phase Ⅲ reached the preset end point.

Dalip Holdings (01921): group 139.7mm 12.7mm DLP140VDLP-T4 high strength and toughness special buckle casing smoothly into the well.

Shanghai Pharmaceutical (02607): consistency Evaluation of folic Acid tablets by generic drugs

Sichuan Chengdu-Chongqing Expressway (00107): win-win Fund Reconstruction and reorganization

Qilu Expressway (01576) plans to set up a partnership to invest in the PPP project.

Nuocheng Jianhua-B (09969) intends to list shares in Science and Technology Innovation Board and will issue no more than 265 million A shares.

Bond bill

Standard Chartered PLC (02888) plans to issue $1.25 billion of fixed interest resets permanent contingent convertible securities

Repurchase cancellation

Zoomlion Heavy Industry Science and Technology (01157) spent 28.8759 million yuan to buy back 4.8614 million A shares on Aug. 4.

Standard Chartered PLC (02888) spent 7.5076 million pounds to buy back 1.2688 million shares on August 3.